Nielsen BioSciences — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Nielsen BioSciences is a commercial-stage biotech with a unique focus on delayed-type hypersensitivity (DTH) skin test antigens for assessing cell-mediated immunity. The company has two approved diagnostic products: CANDIN for Candida albicans sensitivity and SPHERUSOL for Coccidioides immitis (Valley Fever) exposure. Leveraging its DTH platform, Nielsen is pursuing therapeutic applications, most notably a Phase 3 investigational program using CANDIN to treat HPV-associated common warts. As a private company, it operates in niche immunology markets with potential for expansion into broader immunotherapy.

ImmunologyInfectious DiseaseDermatology

Technology Platform

FDA-approved delayed-type hypersensitivity (DTH) skin test antigen platform using standardized biological extracts (Candida albicans, Coccidioides immitis) to assess and potentially modulate cell-mediated immune responses.

Opportunities

The lead therapeutic program in Phase 3 for common warts represents a significant opportunity to enter the large dermatology therapeutics market with a novel immunotherapy.

Success would also validate the DTH platform for broader applications in other localized skin conditions, including potential oncologic indications like non-melanoma skin cancer.

Risk Factors

The company faces high clinical risk as its value is heavily dependent on the success of a single Phase 3 trial.

As a small, private firm, it also carries financial risk in funding late-stage development and commercialization risk in launching a novel therapy in a competitive market.

Competitive Landscape

In diagnostics, Nielsen holds a monopoly on FDA-approved DTH skin tests for Candida and Coccidioides. Therapeutically, for warts, it would compete with a wide range of existing destructive (cryotherapy, salicylic acid) and immunomodulatory (imiquimod, sinecatechins) treatments. Its novel immunostimulant mechanism could differentiate it if proven effective.

More companies in Diagnostics & Precision Medicine →More companies in United States →